News coverage about DarioHealth Corp. (NASDAQ:DRIO) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. DarioHealth Corp. earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.7895942631948 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the media headlines that may have impacted Accern Sentiment’s scoring:

DarioHealth Corp. (DRIO) opened at $1.62 on Wednesday. DarioHealth Corp. has a fifty-two week low of $1.40 and a fifty-two week high of $4.70.

DarioHealth Corp. (NASDAQ:DRIO) last posted its quarterly earnings results on Monday, August 14th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.13). DarioHealth Corp. had a negative return on equity of 626.32% and a negative net margin of 206.95%. The company had revenue of $1.21 million for the quarter.

Separately, Aegis initiated coverage on DarioHealth Corp. in a report on Tuesday, August 29th. They set a “buy” rating and a $3.50 price target on the stock.

ILLEGAL ACTIVITY NOTICE: This report was first published by Watch List News and is the property of of Watch List News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/dariohealth-corp-drio-earns-daily-media-impact-rating-of-0-16/1703560.html.

DarioHealth Corp. Company Profile

DarioHealth Corp, formerly Labstyle Innovations Corp, is a digital health (mHealth) company. The Company is engaged in developing and commercializing a technology providing consumers with laboratory-testing capabilities using smart phones and other mobile devices. The Company’s product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with a pocket-sized, blood glucose monitoring device, Dario Smart Meter.

Insider Buying and Selling by Quarter for DarioHealth Corp. (NASDAQ:DRIO)

Receive News & Ratings for DarioHealth Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.